Key result
Dedicated transcatheter heart valves show emerging potential for native aortic regurgitation in review of current evidence.
Why the study?
Surgical aortic valve replacement is the gold standard for symptomatic AR, but dedicated transcatheter heart valves for TAVR in AR are under development and require evaluation.
This review summarizes current evidence and future studies regarding the use of dedicated transcatheter heart valves for treating aortic regurgitation.
Aortic regurgitation (AR) is a common valvular heart disease with an estimated prevalence of greater than 4% among patients aged greater than 65 years in some series. If left untreated, AR is associated with progression to left ventricular dysfunction and death. Surgical aortic valve replacement is considered the gold standard for the management of symptomatic AR. Several dedicated transcatheter heart valves (THVs) are currently in development. In this review, we highlight the current evidence and future studies evaluating outcomes of dedicated THVs for transcatheter aortic valve replacement in AR.
No takes yet. Share an insight, caveat, or question.
Guddeti et al. (2026) conducted a review in Aortic regurgitation. Transcatheter aortic valve replacement was evaluated. Transcatheter aortic valve replacement for native aortic regurgitation using dedicated transcatheter heart valves is the subject of this review evaluating current evidence and future studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: